Literature DB >> 1845771

HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription.

A E Goldfeld1, K Birch-Limberger, R T Schooley, B D Walker.   

Abstract

An early host defense against infection by RNA or DNA viruses is the induction, within infected cells, of tumor necrosis factor-alpha (TNF-alpha) gene transcription. The protein product of the TNF-alpha gene alone, or together with different types of interferons, inhibits viral propagation in diverse cell types. In this study, the effect of acute and chronic human immunodeficiency virus type 1 (HIV-1) infection on the transcription of the TNF-alpha and interferon-beta (IFN-beta) genes was examined in susceptible monocyte and T-cell lines as well as in primary human mononuclear phagocytes. Although Sendai virus, a prototypic inducer of TNF-alpha and IFN-beta mRNA, induced the transcription of both genes in the monocyte cell lines and TNF-alpha in the T-cell line and in primary mononuclear phagocytes, transcription of these genes was not inducible by HIV-1. Therefore, HIV-1 was able to infect these cells without triggering the transcription of genes encoding proteins important in immediate antiviral cellular defenses. These results may explain in part how HIV-1 is able to establish persistent intracellular infections and escape acute host responses that have evolved to combat viral infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845771

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  15 in total

Review 1.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

Review 2.  Gaining a foothold: how HIV avoids innate immune recognition.

Authors:  Nan Yan; Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2010-11-29       Impact factor: 7.486

Review 3.  Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat.

Authors:  James V Falvo; Shahin Ranjbar; Luke D Jasenosky; Anne E Goldfeld
Journal:  Am J Respir Cell Mol Biol       Date:  2011-08-18       Impact factor: 6.914

Review 4.  Dendritic Cell Immune Responses in HIV-1 Controllers.

Authors:  Enrique Martin-Gayo; Xu G Yu
Journal:  Curr HIV/AIDS Rep       Date:  2017-02       Impact factor: 5.071

5.  Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages.

Authors:  P D Smith; S S Saini; M Raffeld; J F Manischewitz; S M Wahl
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice.

Authors:  Lee Adam Wheeler; Radiana T Trifonova; Vladimir Vrbanac; Natasha S Barteneva; Xing Liu; Brooke Bollman; Lauren Onofrey; Sachin Mulik; Shahin Ranjbar; Andrew D Luster; Andrew M Tager; Judy Lieberman
Journal:  Cell Rep       Date:  2016-05-12       Impact factor: 9.423

Review 7.  The use of GM-CSF in AIDS.

Authors:  D T Scadden
Journal:  Infection       Date:  1992       Impact factor: 3.553

8.  Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells.

Authors:  V A Boussiotis; L M Nadler; J L Strominger; A E Goldfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1.

Authors:  Nan Yan; Ashton D Regalado-Magdos; Bart Stiggelbout; Min Ae Lee-Kirsch; Judy Lieberman
Journal:  Nat Immunol       Date:  2010-09-26       Impact factor: 25.606

10.  Human Three Prime Repair Exonuclease 1 Promotes HIV-1 Integration by Preferentially Degrading Unprocessed Viral DNA.

Authors:  Benem-Orom Davids; Muthukumar Balasubramaniam; Nicklas Sapp; Prem Prakash; Shalonda Ingram; Min Li; Robert Craigie; Thomas Hollis; Jui Pandhare; Chandravanu Dash
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.